Icosavax_Logo.jpg
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
12 déc. 2023 02h05 HE | Icosavax, Inc.
Icosavax, Inc. Announces Agreement to be Acquired by AstraZeneca
Icosavax_Logo.jpg
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
12 déc. 2023 02h00 HE | Icosavax, Inc.
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
Icosavax_Logo.jpg
Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14 nov. 2023 16h05 HE | Icosavax, Inc.
- Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV - - IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023...
Icosavax_Logo.jpg
Icosavax Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14 août 2023 16h05 HE | Icosavax, Inc.
- Positive topline interim Phase 1 results for bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults - - Positive twelve-month immunogenicity data and initial proof-of-concept...
Icosavax_Logo.jpg
Icosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination Potential
08 août 2023 16h05 HE | Icosavax, Inc.
- In new data from Icosavax’s IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) - ...
Icosavax_Logo.jpg
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults
20 juin 2023 08h00 HE | Icosavax, Inc.
- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 - SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) --...
Icosavax_Logo.jpg
Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update
10 mai 2023 16h05 HE | Icosavax, Inc.
- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term...
Icosavax_Logo.jpg
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
30 mars 2023 16h05 HE | Icosavax, Inc.
- FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate - - Completed dosing in ongoing Phase 1 study of...
Icosavax_Logo.jpg
Icosavax to Participate in the Upcoming Healthcare Conferences
28 févr. 2023 08h00 HE | Icosavax, Inc.
SEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax_Logo.jpg
Icosavax Granted FDA Fast Track Designation for IVX-A12
21 févr. 2023 08h00 HE | Icosavax, Inc.
SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...